Skip to main content
Signal8
Launch Terminal

Cartesian Therapeutics, Inc. (RNAC)

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Cartesian Therapeutics, Inc. logo

Cartesian Therapeutics, Inc.

NASDAQ:RNACHealthcare
-3.85%$6.49
AH$6.49+0.00%vs close
Mkt Cap$196.36M
Float–
O/S30.26M
Vol
$ Vol
RVOL
Inst Own28.7%
Earnings
Dilution
Cartesian Therapeutics, Inc. logoNASDAQ:RNAC$6.49-3.85%
Phase Distribution
19 lead-sponsored trials·5 active·7 completed
Phase 19
Phase 1/22
Phase 27
Phase 31
Status Overview
Recruiting2
Active, not recruiting3
Completed7
Stopped7

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Active, not recruiting

    Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis

    Decartes-08

    Myasthaenia Gravis

    Enrollment
    128
    Start
    May 2025
    Primary Completion
    Dec 2026est.
    Completion
    Sep 2027est.
    NCT06799247
  • Phase 2
    Completed

    Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid

    SEL-212, SEL-037

    Gout Chronic, Hyperuricemia

    Enrollment
    152
    Start
    Oct 2016
    Primary Completion
    Dec 2018
    Completion
    Jan 2019
    NCT02959918
  • Phase 2
    Completed

    A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy

    SEL-212, KRYSTEXXA®

    Chronic Gout

    Enrollment
    170
    Start
    May 2019
    Primary Completion
    Aug 2020
    Completion
    Aug 2020
    NCT03905512
  • Phase 2
    Active, not recruiting

    Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

    Descartes-08

    Myasthenia Gravis, Generalized

    Enrollment
    30
    Start
    Dec 2019
    Primary Completion
    Jan 2026
    Completion
    Sep 2026est.
    NCT04146051
  • Phase 2
    Completed

    Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

    Descartes 11

    Multiple Myeloma

    Enrollment
    5
    Start
    Feb 2021
    Primary Completion
    Feb 2022
    Completion
    Apr 2022
    NCT04436029
  • Phase 2
    Terminated

    Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

    Descartes 08

    Myeloma Multiple

    Enrollment
    13
    Start
    Dec 2021
    Primary Completion
    Aug 2022
    Completion
    Nov 2022
    NCT04816526
  • Phase 2
    Active, not recruiting

    Descartes-08 for Patients With Systemic Lupus Erythematosus

    Descartes-08

    Systemic Lupus Erythematosus (SLE)

    Enrollment
    6
    Start
    Feb 2024
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2027est.
    NCT06038474
  • Phase 2
    Recruiting

    Descartes-08 in Autoantibody Myositis

    Descartes-08

    Antisynthetase Syndrome

    Enrollment
    60
    Start
    Apr 2026
    Primary Completion
    Nov 2027est.
    Completion
    May 2028est.
    NCT07391605
  • Phase 1/2
    Withdrawn

    A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA

    SEL-302

    Methylmalonic Acidemia (MMA)

    Enrollment
    0
    Start
    Dec 2022
    Primary Completion
    Aug 2025est.
    Completion
    Aug 2029est.
    NCT05778877
  • Phase 1/2
    Recruiting

    Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

    Descartes-08

    Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV) +2

    Enrollment
    50
    Start
    Jan 2026
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2028est.
    NCT07089121
  • Phase 1
    Completed

    Safety and Pharmacodynamics of SEL-068 Vaccine in Smokers and Non-Smokers

    SEL-068, Saline

    Smoking Cessation

    Enrollment
    82
    Start
    Nov 2011
    Primary Completion
    Jan 2013
    Completion
    Mar 2013
    NCT01478893
  • Phase 1
    Completed

    Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels

    SEL-037 (pegsiticase)

    Gout

    Enrollment
    22
    Start
    May 2015
    Primary Completion
    Nov 2015
    Completion
    Jul 2016
    NCT02464605
  • Phase 1
    Completed

    Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels

    SEL-110, SEL-212

    Gout

    Enrollment
    63
    Start
    Dec 2015
    Primary Completion
    Dec 2016
    Completion
    Dec 2016
    NCT02648269
  • Phase 1
    Completed

    Safety and Pharmacodynamcis of SELA-070 Nicotine Vaccine in Smokers

    SELA-070, Saline

    Smoking Cessation

    Enrollment
    72
    Start
    May 2017
    Primary Completion
    Oct 2018
    Completion
    Oct 2018
    NCT03148925
  • Phase 1
    Terminated

    Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

    Descartes-08, Fludarabine

    Multiple Myeloma

    Enrollment
    32
    Start
    Mar 2018
    Primary Completion
    Apr 2021
    Completion
    Jun 2021
    NCT03448978
  • Phase 1
    Terminated

    Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma

    Descartes-11, Fludarabine

    Multiple Myeloma

    Enrollment
    20
    Start
    Aug 2019
    Primary Completion
    May 2021
    Completion
    Jun 2021
    NCT03994705
  • Phase 1
    Terminated

    Study of Descartes-30 in Acute Respiratory Distress Syndrome

    Descartes 30

    Acute Respiratory Distress Syndrome, Covid19

    Enrollment
    12
    Start
    Feb 2021
    Primary Completion
    Sep 2022
    Completion
    Sep 2023
    NCT04524962
  • Phase 1
    Terminated

    Descartes-25 in Relapsed/Refractory Multiple Myeloma

    Descartes-25

    Multiple Myeloma, Relapse Multiple Myeloma

    Enrollment
    9
    Start
    Nov 2021
    Primary Completion
    May 2023
    Completion
    Nov 2024
    NCT05113342
  • Phase 1
    Terminated

    Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma

    Descartes-15

    Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    Enrollment
    4
    Start
    Jun 2024
    Primary Completion
    Apr 2025
    Completion
    Nov 2025
    NCT06304636
Search ClinicalTrials.gov for “Cartesian Therapeutics”